Identification of a bacteriocin-like compound from Lactobacillus plantarum with antimicrobial activity and effects on normal and cancerogenic human intestinal cells by A. De Giani et al.
De Giani et al. AMB Expr            (2019) 9:88  
https://doi.org/10.1186/s13568-019-0813-6
ORIGINAL ARTICLE
Identification of a bacteriocin-like 
compound from Lactobacillus plantarum 
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Abstract 
In this paper, we demonstrate that the antimicrobial activity of L. plantarum PBS067 strain against antagonist micro-
organisms was mediated by the production of a bacteriocin-like compound secreted at the stationary phase of the 
growth. The novel bacteriocin-like compound, designed plantaricin P1053, was identified by using sorption–desorp-
tion method, butanol extraction and SEC-HPLC. The molecular mass of plantaricin P1053 was shown to be 1053 Da 
by ESI-MS analysis. Plantaricin P1053 exhibited a broad-spectrum antimicrobial activity against Gram-positive bacteria 
as S. aureus and Gram-negative bacteria as E. coli. In addition to the antimicrobial activity, the isolated bacteriocin-
like compound showed effects on normal and cancerogenic epithelial intestinal cell lines through an enhancing of 
viability of healthy cells and a proliferation reduction of cancer cells. Moreover, in this paper we demonstrate that 
the isolated bacteriocin-like compound acts on healthy cells through the epidermal growth factor receptor (EGFR) 
pathways. In conclusion, plantaricin P1053 isolated from L. plantarum PBS067 strain could represent one of the first 
multifunctional bacteriocin-like compound acting on human epithelial intestinal cells.
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Introduction
Probiotics are recognized as live microorganisms that 
confer a health benefit to the host when administered 
in adequate amounts (FAO/WHO 2001). These bacte-
ria exert health-promoting properties, including the 
effects on specific tissues, particularly on the intestine. 
Most of the mechanisms involve the modification of 
the gut microbiota because of the immune-modulating 
attitude on the intestinal tissues (Valeur et  al. 2004) 
or the release of essential micronutrients in the guts, 
such as group B vitamins (LeBlanc et  al. 2011) and 
the production of substances such as organic acids or 
bacteriocins with antagonistic activity against poten-
tial pathogens (Servin 2004). Among the antimicrobial 
substances produced by these bacteria, bacteriocins 
are interesting because of their several applications, 
like natural food preservatives or novel therapeutic 
agents to complement conventional antibiotics (Trivedi 
et  al. 2013). The biochemical characterization can be 
an important goal to understand their mode of action. 
In fact, bacteriocins are ribosomally synthesized anti-
microbial peptides or complex proteins secreted by 
various Gram-positive and Gram-negative bacteria 
(Desriac et al. 2010). Based on biochemical properties, 
bacteriocins have been divided into three groups: fam-
ily of lantibiotics (Class I), small non-modified peptides 
resistant to heat and pH (Class II), larger heat-labile 
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proteins (Class III) (Klaenhammer 1993; Porto et  al. 
2017). Class II is subdivided into four sub-groups. One 
of the four sub-groups is the Class IIA that contains 
bacteriocins known as “pediocin-like” peptides whose 
synthesis requires four genes encoding proteins regu-
lated by a quorum sensing mechanism (Da Silva et  al. 
2014; Diep et al. 2009). These proteins and peptides are 
known for their antimicrobial properties against some 
potential pathogens like Escherichia coli, Staphylococ-
cus aureus and Bacillus spp. (Ahmad et al. 2017; Zhao 
et  al. 2016). Many of these bacteriocins are produced 
from L. plantarum strains. Some of them have been 
studied, such as L. plantarum JLA-9 (Zhao et al. 2016), 
L. plantarum ZJ5 (Song et  al. 2014), L. plantarum 
ZJ008 (Zhu et al. 2014). The bacteriocins isolated from 
these strains have the peculiarity to have a very low 
molecular weight around 1000–3000 Da.
The mechanism of action of bacteriocins is not well 
understood, but in literature it is reported that they can 
kill target bacteria by membrane permeabilization or by 
binding to a specific membrane protein called “bacteri-
ocin receptor”, where the interaction between peptide 
and receptor protein leads to membrane leakage and cell 
death (Oppegard et  al. 2016). This mechanism explains 
both the extreme potency of many bacteriocin-like com-
pounds and their narrow inhibition spectra. However, 
we still lack knowledge about the nature of the interac-
tion between these compounds and receptors, and also 
the interaction between these compounds and intestinal 
human cells. Some authors reported that bacteriocins 
can exert some beneficial effects on humans, because 
of their interaction with the intestinal epithelia. It is 
reported that metabolites from probiotic cultures showed 
an anti-proliferative effect on human colon cancer (do 
Lee et al. 2008; Ma et al. 2010; You et al. 2004). Moreo-
ver, Ma et al. (2010) speculated that the activity is medi-
ated through the inhibition of Epidermal Growth Factor 
Receptor (EGFR) kinase activity. Also Yan et  al. (2011) 
described the effect of a bacteria-derived soluble protein 
p40 from Lactobacillus rhamnosus GG, which was able to 
prevent cytokine induced apoptosis in intestinal epithe-
lial cell lines through the regulation of the activation of 
Akt. Nevertheless, probiotic effects are strain dependent 
and different species might have different mechanisms of 
action (Dimitrovski et al. 2014).
In a previous work (Presti et al. 2015), strains of Lacto-
bacillus spp. and Bifidobacterium spp. were characterized 
for their probiotic properties, among which there was 
the antimicrobial activity. Previous results of cell-free 
supernatants at neutral and acidic pH from all selected 
probiotic strains and the direct growth inhibition of the 
potential pathogens on the LABs, made us speculate that 
bacteriocin-like compounds can be produced, especially 
from Lactobacillus plantarum strain PBS067, showing a 
strong antimicrobial activity.
The aim of this work was to demonstrate that the anti-
microbial activity exhibited from L. plantarum strain 
PBS067 against antagonist microorganisms was mediated 
by a bacteriocin-like compound, produced and secreted 
in the medium during the growth of the strain. The puri-
fied compound was described as likely belonging to an 
uncommon group of bacteriocins (Class II). The novelty 
of the work is that plantaricin P1053 revealed to possess 
both an antimicrobial activity against pathogenic bacte-
ria and an effect on host cells through an enhancement 
of healthy cells viability and a reduction of cancerogenic 
intestinal cells viability.
Materials and methods
Strains and culture conditions
Lactobacillus plantarum strain PBS067 (Presti et  al. 
2015) (deposited at DSMZ culture collection as DSM 
24937), isolated from the feces of healthy humans, was 
supplied from a private collection (Principium Europe 
S.r.l., now Roelmi Hpc). L. plantarum PBS067 was 
selected for this study for its ability to exhibit a strong 
antimicrobial activity against different human pathogens 
as E. coli, P. aeruginosa, S. aureus, E. faecium after 24 h of 
incubation at 37 °C. Unless otherwise specified, L. plan-
tarum was cultured in deMan, Rogosa and Sharpe (MRS) 
medium. The cultures were incubated at 37  °C under 
anaerobic conditions using anaerobic atmosphere gen-
eration bags (Anaerogen, Oxoid).
As antagonistic microorganisms for antimicrobial 
activity assay, E. coli ATCC 25922, Staphylococcus aureus 
ATCC 6538, Pseudomonas aeruginosa ATCC 9027, and 
Enterococcus faecalis ATCC 2922 were employed. The 
cultures were performed in Luria–Bertani medium (LB) 
agar, modified by Lennox known as LD (Lennox 1995), at 
37 °C in aerobiosis.
Screening for antimicrobial activity
The antimicrobial activity was determined by the well 
diffusion agar assay (WDAA) for lactobacilli according 
to the protocol of Santini et al. (2010) with some modi-
fications. Overnight MRS cultures were centrifuged 
at 7000  rpm at 4  °C for 15  min. The pHs of the super-
natants were measured and recorded. The supernatants 
that were naturally at pH 4 were collected and filtered 
through 0.22-µm pore filter membranes to remove any 
residual bacterial cell (CFS, Cell Free Supernatant). The 
CFS antimicrobial activity was measured against E. coli, 
P. aeruginosa, E. faecalis, S. aureus bacteria. In particular, 
the antagonist strains were inoculated into LD medium 
and let to grow until the optical density at 600  nm 
 (OD600) was 0.5, corresponding to around  107 CFU/mL. 
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2.5% (v/v) of the culture was inoculated into 20 mL of LD 
agar and the plates were allowed to solidify. Four wells of 
8 mm in diameter were made on each agar plate with a 
sterile glass cylinder. 50 µL and 100 µL of L. plantarum 
PBS067 culture supernatant (CFS) was dispensed into 
each well; neutralized-acidified PBS067 CFS, not-inoc-
ulated and acid not-inoculated MRS (100 µL) were used 
as controls. Plates were incubated overnight at 37  °C in 
aerobiosis. The growth inhibition haloes were measured.
The same method was used to test the antimicrobial 
activity of the concentrated crude extract and the puri-
fied bacteriocin-like compound against E. coli, and S. 
aureus as representative strains of Gram-negative and 
Gram-positive bacteria, respectively.
Purification of the bacteriocin‑like compound from culture 
medium of L. plantarum
Adsorption/desorption method (step 1)
A modification of Yang et  al. (1992) extraction method, 
based on the hydrophobicity and the charge of the com-
pounds secreted by the cells, was used in order to iden-
tify bacteriocin-like compounds from L. plantarum 
strain PBS067 cultures.
First, the strain was pre-cultured in 15  mL of MRS 
medium at 37  °C overnight, in anaerobic conditions. 
Then, the pre-culture was inoculated in four flasks each 
containing 300 mL of MRS medium with an initial 0.01 
 OD600. The flasks were incubated at 37  °C, for 16  h, in 
microaerophilic conditions. Final cultures had an  OD600 
between 3 and 4, which corresponded to the initial 
latency period.
The established method allowed to partially purify cell 
secreted compounds on the basis of the pH of extrac-
tion medium promoting the adsorption/desorption of 
these molecules from the lactic acid bacteria membrane. 
Therefore, in the step 1 the cultures were neutralized 
to pH 6.5 with NaOH 1.5 M and let to stand for 30 min 
at room temperature. Then, they were centrifuged at 
7000  rpm at 4  °C for 10  min. After the cells had been 
washed with a phosphate buffer (0.1 M pH 6.5), they were 
resuspended in 60 mL of NaCl 0.1 M at pH 2 and mixed 
with a magnetic stirrer for 1  h at 4  °C. Cell suspension 
was then centrifuged at 16,000g for 30 min at 4 °C. This 
fraction of the supernatant containing the bacteriocin-
like molecule (called crude extract) was used for further 
analysis and characterization.
An aliquot of this fraction containing the bacteriocin-
like molecule was tenfold concentrated and used for 
WDAA (see above) in order to assess its antimicrobial 
activity using 100 µL of the concentrated crude extract. 
100 µL of cell free supernatant (CFS) (see above) and 
100 µL of NaCl 0.1 M at pH 2 were used as positive and 
negative controls, respectively. The growth inhibition 
zones around the wells were measured.
Before proceeding with the purification, the pH of the 
fraction was increased up to 10–11 with NaOH 1.5  M, 
and then the solution was lyophilized.
Organic phase extraction (step 2)
The lyophilized crude extract (deriving from 300  mL of 
supernatant) was extracted with 10  mL of n-butanol 
under agitation, at room temperature for 20 h. This step 
was repeated twice. Then, the butanol extracts were fil-
tered through a paper filter and the solvent was evapo-
rated. The residue was resuspended in 1 mL of methanol 
and analysed in SEC-HPLC.
Size exclusion chromatography (SEC) HPLC (step 3)
SEC analyses were performed with a Waters 600E deliv-
ery system equipped with Waters 486 UV–Vis detector 
and a Phenogel 5 100 A, Phenomenex, 300 × 4.6  mm 
column eluted in isocratic conditions with methanol at 
a flow rate of 0.3  mL/min. The eluted compounds were 
detected at 254 nm and their retention times were com-
pared with the retention time of the standard nisin, the 
model bacteriocin from Enterococcus lactis. In these 
conditions, the retention time of nisin was 11.8 min. An 
aliquot of the eluted compound containing the bacteri-
ocin-like molecule was tenfold concentrated and used for 
WDAA in order to assess its antimicrobial activity.
Characterization of the bacteriocin‑like plantaricin P1053 
by ESI‑full mass spectrometry (MS)
The eluted compound containing the bacteriocin-like 
molecule was analysed by the electrospray ionization 
ESI-full mass spectrometry. The analysis was performed 
on LCQ Fleet ion trap mass spectrometer. The MS was 
operated in positive ionization mode acquiring spectra in 
the m/z range of 200 to 2000.
Effects of proteinase K enzyme on the stability 
of the purified bacteriocin‑like compound and total 
protein concentration
In order to evaluate the purified bacteriocin-like mol-
ecule sensitivity to the proteinase K (pH 7.5; Sigma 
Aldrich, Italy), the bacteriocin-like compound was 
treated with 1  mg/mL (final concentration) proteinase 
K (ratio 1:5) at its optimal pH. After 3 h of incubation at 
37 °C, the reaction was stopped at 4 °C. Subsequently, the 
sample was adjusted to pH 2 using 6 M HCl and assayed 
for antimicrobial activity. The bacteriocin-like molecule 
at the original pH (pH 2) without any heat or enzyme 
treatments was used as the control sample. The agar 
well diffusion assay was carried out to test the remaining 
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activity against the indicator strain E. coli ATCC25922 
(Santini et al. 2010).
The total protein concentration was assessed on the 
partial purified and purified bacteriocin-like molecule 
extracts using a Pierce BCA protein assay kit (Thermo 
Fisher Scientific, Italy) according to the manufacturer’s 
protocol. Protein concentrations were calculated from 
the standard curve by 20 mg/mL bovine albumin serum.
Maintenance and growth of cell lines for in vitro tests
CCD 841 (ATCC CRL-1790) healthy colon cell 
line (Thompson et  al. 1985) were grown in EMEM 
medium supplemented with heat-inactivated 10% FBS, 
2  mM  l-glutamine, 1% non-essential amino acids, 100 
U/mL penicillin and 100 µg/mL streptomycin and main-
tained at 37 °C in a humidified 5%  CO2 incubator.
E705 colon cancer cell line (supplied by IRCCS Foun-
dation, Cancer National Institute) (Mozzi et al. 2015) was 
grown in DMEM medium supplemented with heat-inac-
tivated 10% FBS, 2 mM l-glutamine, 100 U/mL penicillin 
and 100 µg/mL streptomycin and maintained at 37 °C in 
a humidified 5%  CO2 incubator.
All the reagents for cell culture were supplied by Euro-
Clone (EuroClone S.p.A, Pero (MI), Italy).
Viability assay
Cell viability was assessed using an in vitro MTT based 
toxicology assay kit (Sigma). Cells were seeded in a 
96-well micro titer plates at a density of 8 × 104 cells/100 
µL and incubated overnight. The attached cells were 
treated with a range of plantaricin P1053 up to 1  µg/
mL. After 48  h of treatment, MTT test was performed 
according to the manufacturer’s protocol and absorption 
was measured at 570  nm using a micro plate reader to 
assay the effect of plantaricin P1053 on healthy CCD 841 
cells and colon cancer E705 cells. Results were expressed 
as mean values ± SD of three determinations.
Protein extraction from treated cell lines and analysis
After treatment with plantaricin P1053 at 0 min, 30 min, 
1  h, 3  h and 24  h, cells were washed with ice-cold PBS 
and lysed in RIPA buffer, containing protease and phos-
phatase inhibitors and 1  mM PMSF. After lysis on ice, 
homogenates were obtained by passing crude extracts five 
times through a blunt 20-gauge needle fitted on a syringe 
and subsequently centrifuging them at 14,000  rpm for 
30  min at 4  °C. Supernatants were analyzed for protein 
content by the BCA protein assay (Smith et al. 1985).
SDS-Page and western blot were carried out by stand-
ard procedures. Thirty micrograms of proteins were sep-
arated on 10% acryl-amide/bis-acrylamide SDS-PAGE, 
transferred onto a nitrocellulose membrane (Millipore, 
Billerica, MA), probed with the appropriate antibodies 
and visualized using ECL detection system (Millipore). 
Protein levels were quantified by densitometry of immu-
noblots using ScionImage software (Scion Corp., Fre-
drick, MD). We used the following primary antibodies 
(all purchased by Cell signaling Technology, Danvers, 
MA): anti-EGFR (dilution 1:1000), anti-phospho-EGFR 
(Tyr 1068; dilution 1:1000), anti-p44/42 MAPK (Erk1/2; 
dilution 1:1000), anti-phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204; dilution 1:1000), anti-Akt (dilution 
1:1000), anti-phosho-Akt (Ser473; dilution 1:1000) and 
anti-GAPDH (dilution 1:10,000). IgG HRP-conjugated 
secondary antibodies (purchased by Cell Signaling Tech-
nology) were diluted 1:10,000.
Statistical analysis
Experiments were performed in triplicate and results 
were presented as mean values ± standard deviation. The 
statistical relevance was assessed by Student’s t test. The 
significance was defined as p value < 0.05.
Results
Identification of antimicrobial activity of L. plantarum 
strain PBS067
Lactobacillus plantarum strain PBS067 was grown until 
reaching the stationary phase of the cells and the cell free 
supernatant (CFS) was used in the antimicrobial activity 
through the well diffusion agar assay. A halo of growth inhi-
bition of the antagonist bacteria was observed and meas-
ured (Table 1). Results showed a halo of inhibition with a 
diameter of 18 mm ± 0.2 for E. coli and 20 mm ± 0.2 for S. 
aureus as representative Gram-negative and Gram-positive 
bacteria, respectively.
Results were compared to the acidified non-inoculated 
medium as negative control, in order to exclude that 
the inhibition was caused by the low pH of the medium 
after the growth. Moreover, obtained data showed that 
the antimicrobial activity was also maintained when the 
Table 1 Dimension of  the  growth halo inhibition 
measured by  CFS from  L. plantarum PBS067 
against the antagonist bacteria
The measures of the inhibition zone are expressed in mm
a The concentration of the solution containing the plantaricin P1053 was of 
200 µg/mL
Antagonist bacteria Halo inhibition by L. 
plantarum PBS067 (mm)
50 µLa 100 µLa
Escherichia coli ATCC 25922 18 ± 0.2 35 ± 0.2
Enterococcus faecalis ATCC 2922 10 ± 0.5 20 ± 0.5
Pseudomonas aeruginosa ATCC 9027 20 ± 0.5 40 ± 0.5
Staphylococcus aureus ATCC 6538 20 ± 0.2 40 ± 0.2
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supernatant was neutralized and then brought again to 
acid pH, as reported as an example for E. coli in Fig. 1. For 
this reason, we hypothesized that the strain PBS067 was 
able to produce bioactive bacteriocin-like compounds 
inhibiting the growth of the tested antagonist bacteria. 
As the bacteriocin-like compounds produced by lacto-
bacilli are strain-specific and with a peculiar kind of bio-
logical activity, we decided to isolate and characterize the 
bioactive compounds produced by L. plantarum PBS067 
strain and to test their range of antimicrobial activity.
Purification of the bacteriocin‑like compound from L. 
plantarum strain PBS067
Bacteriocin-like compounds were isolated from cell 
free supernatant (CFS) of L. plantarum PBS067 culture 
using the modified method described by Yang et  al. 
(1992) based on the hydrophobicity and the charge 
of the compounds secreted by cells. The established 
method allowed to extract and partially purify the 
bacteriocin-like molecules in a fraction called crude 
extract. The crude extract was screened for the anti-
microbial activity using the agar well diffusion assay 
to verify that this property was maintained after this 
extraction phase (Fig.  2A, step 1). Results were com-
pared to NaCl 0.1  M at pH 2 as negative control and 
CFS as positive control. The assay showed an increase 
in specific antimicrobial activity in this fraction (crude 
Fig. 1 Antimicrobial activity of Lactobacillus plantarum PBS067 cell 
free supernatant. The antimicrobial activity of L. plantarum PBS607 
cell free supernatant (CFS) was determined as halo of growth 
inhibition of E. coli ATCC 25922 through the agar well diffusion 
assay. The figure shows the inhibition zones produced by CFS (A), 
by neutralized-acidified CFS (B), not inoculated MRS at pH 4 (C), not 
inoculated MRS (D) against E. coli ATCC 25922
Adsorption Desorption
Antimicrobial activity of 
the crude extract
A-Step 1
L. plantarum
cell membrane
L. plantarum
cell membrane
pH = 6.5 pH = 2.0
++ +
++ +
Antimicrobial activity of the 
partially purified extractExtraction with n-butanol
B-Step 2
Water Butanol
A
bsorbance
Time (min)
Antimicrobial activity of 
the purified extract
C-Step 3
Fig. 2 Step-by-step purification and antimicrobial activity of the bacteriocin-like compound. The antimicrobial activity of the purified extract was 
verified through agar well diffusion assay. Step 1 of purification and inhibition halo produced by the crude extract obtained after adsorption/
desorption method (A), step 2 of purification and antimicrobial activity of the partial purified extract through an extraction with n-butyl alcohol (B), 
step 3 of purification and the growth inhibition of the eluted bacteriocin-like compound (C). All samples were tested against E. coli ATCC 25922
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extract) measured through the dimension of the inhi-
bition halo. The activity was not shown at neutral and 
alkaline pH, but it was recovered when the pH was 
lowered to 4, the lactobacilli physiological pH.
Then, the lyophilized crude extract from L. plan-
tarum supernatant was submitted to another step of 
purification performed with n-butyl alcohol. After the 
antimicrobial activity of the partially purified extract 
deriving from this second step was demonstrated, 
the obtained extract was analyzed and characterized 
(Fig. 2B, step 2).
The extract deriving from n-butanol extraction was 
first analyzed in HPLC by Size Exclusion Chromatog-
raphy (SEC). The UV/visible absorption spectra of the 
sample revealed a maximum absorbance–wavelength 
at 254 nm. Results from SEC-HPLC analysis showed a 
main peak at 254 nm with a retention time of 14.5 min 
whose eluate maintained the antimicrobial activity 
(Fig. 2C, step 3). As a preliminary characterization, the 
purified extract was compared with the only reference 
standard available, the 3354.0 Da nisin from Lactococ-
cus lactis. Based on the comparison of the retention 
times, the main peak of the extract had a molecular 
weight lower than 3354.0  Da. On this basis, the ESI 
mass spectrometry analysis of the purified extract will 
be used to thoroughly characterize the bacteriocin-like 
compound and determine the molecular weight.
Effects of proteinase K on the stability of the purified 
bacteriocin‑like compound and total protein concentration
The sensitivity of the purified bacteriocin-like mol-
ecule to the proteinase K was evaluated after 3  h 
of incubation at 37  °C with the hydrolytic enzyme. 
Results indicated that the treatment with proteinase 
K showed the expected effect on the purified bacte-
riocin-like molecule; in fact, the inhibitory activity of 
the purified bacteriocin-like molecule against E. coli 
strain ATCC25922 was completely lost (Fig.  3) after 
the treatment.
The crude extract and the purified bacteriocin-like 
molecule were positive to BCA protein assay. In par-
ticular, the total protein concentration of the crude 
extract was 200  µg/mL, while the corresponding 
expected concentration was 3900  µg/mL based on the 
initial dry weight of the supernatant. After the purifica-
tion of the bacteriocin-like molecule, the total protein 
concentration was 4000 µg/mL, while the correspond-
ing calculated concentration was 4140 µg/mL based on 
the lyophilized amount. Results demonstrated that the 
bacteriocin-like compound was a protein-like molecule 
and that after purification a 100% enrichment of pro-
teins was determined.
Characterization of the bacteriocin‑like compound by ESI 
mass spectrometry
We decided to perform an ESI-full MS analysis on the 
enriched fraction of our bacteriocin-like compound. 
This analysis revealed that the extract contained a main 
compound with a molecular weight of 1053  Da (Fig.  4) 
(from here named plantaricin P1053); smaller than the 
most important plantaricins described in literature as 
for example plantaricin C19 (3.8 kDa) from L. plantarum 
C19 (Atrih et al. 2001), but with a molecular weight simi-
lar to those of JLA-9 from L. plantarum JLA-9 (Zhao 
et al. 2016). The weight is in agreement with the results 
obtained by SEC-HPLC chromatography.
Antimicrobial spectrum activity of plantaricin P1053
Antimicrobial spectrum activity of the purified planta-
ricin P1053 was determined by the measure of the halo 
inhibition of the growth against E. coli and S. aureus as 
representative of Gram− and Gram+ antagonist bacte-
ria, respectively. Results are showed in Fig. 5. Plantaricin 
P1053 exhibited a notable antimicrobial activity against 
both E. coli and S. aureus with a growth inhibition 
zone of 2.5  cm and 3.0  cm, respectively. The inhibition 
D
C
B
A
E
Fig. 3 Effect of proteinase K on the purified bacteriocin-like 
compound. The antimicrobial activity of the purified bacteriocin-like 
compound was determined as halo of growth inhibition of E. 
coli ATCC 25922 through the agar well diffusion assay. The Figure 
shows the lack of inhibition zone produced by the treatment of 
the bacteriocin-like compound by proteinase K (A); the inhibition 
halo produced by the no-treated bacteriocin-like compound after 
incubation at 37 °C and pH 7.5 (the proteinase K optimal pH) (B); 
the inhibition zone produced by the untreated bacteriocin-like 
compound at pH 2 (its optimal pH), as a positive control of the test 
(C); the lack of inhibition halo produced by the negative control NaCl 
0.1 M pH 7.5 (buffer of the reaction with proteinase K) (D); and the 
lack of inhibition halo produced by the negative control NaCl 0.1M 
pH 2 (buffer for bacteriocin-like molecule activity) (E)
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spectrum of plantaricin P1053 appeared to be relatively 
wide because of the activity against both Gram-negative 
and Gram-positive bacteria.
In addition, the minimum inhibition growth concen-
tration (MIC) of plantaricin P1053 against these bacteria 
was determined and data are reported in Table 2. Results 
Fig. 4 Analysis of the bacteriocin-like compound by mass spectrometry. Full scan mass spectrum of the extract in positive ESI ion detection mode 
with one main fragment showing m/z = 1053.05 Da. ITMS + c HESI E full MS (1.16 e4). The area around the M+ is enlarged in the insert
A
B D 
C 
I II
A
B 
C
D 
Fig. 5 Antimicrobial spectrum activity of plantaricin P1053. The antimicrobial spectrum activity of the plantaricin P1053 was verified through the 
inhibition growth halo in the agar well diffusion assay. The first panel shows the inhibition haloes against E. coli ATCC 25922 and the second panel 
against S. aureus ATCC 6538 produced by the plantaricin P1053 at neutral pH (A), by the plantaricin P1053 at pH 2 (B), by the NaCl 0.1 M at pH 2 (C) 
and by NaCl 0.1 M at pH 6.5 (D) as negative controls
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show that the MIC values are 7.8 µg/mL for E. coli strain 
ATCC25922 and 31  µg/mL for S. aureus strain ATCC 
6538, respectively.
These data indicated an antimicrobial activity similar to 
those of the plantaricin JLA-9, which presented a MIC of 
16 µg/mL against S. aureus and 64 µg/mL against E. coli 
strain ATCC25922.
In vitro test of plantaricin P1053 on healthy colon CCD 841 
cell line
In order to verify that plantaricin P1053 could have ben-
eficial effects also on human intestinal epithelial cells, we 
initially verified the viability of the healthy colon CCD 
841 cell line in the presence of the obtained plantaricin. 
To this end, the viability of CCD 841 cells treated with 
1 µg/mL of plantaricin P1053 was assayed by MTT test. 
Results reported in Fig. 6 show an increase in CCD 841 
cell viability of about 20%. It appears that plantaricin 
P1053 acts on healthy cells as previously demonstrated 
for a few bacteriocins isolated from lactobacilli (Wang 
et al. 2014; Tao et al. 2005). So, we decided to investigate 
whether the isolated bacteriocin-like molecule was able 
to influence some pathways in healthy human cell lines.
To evaluate a possible role for plantaricin P1053 in the 
complex pathway triggered by EGFR activation in healthy 
cell lines, cells were treated with 1 µg/mL of plantaricin 
P1053 for different times (0  min, 30  min, 1  h, 3  h and 
24  h). We decided to use CCD 841 cells because they 
represent the wild type cell line (healthy cells) for all the 
proteins involved in EGFR pathway (Akt and Erk proteins 
are not mutated).
Western blot analysis showed an activation of EGFR 
pathway in the healthy human cell line CCD 841. Plan-
taricin P1053 administration to CCD 841 cells led 
to an increase of phospho-Akt as an early response 
(30 min–3 h) and a significant decrease as a late response 
(24  h). Erk showed a peak in its phosphorylation level 
after 30  min of exposure to the bacteriocin-like com-
pound, that decreased gradually from 1 to 3 h after the 
administration, becoming completely unphosphorylated 
(ND) after 24 h (Fig. 7).
In vitro test of plantaricin P1053 on colon cancer E705 cell 
line
A possible beneficial effect of plantaricin P1053 on can-
cerogenic epithelial intestinal cells was also evaluated. 
A viability test of E705 cells treated with different con-
centrations of plantaricin P1053 was performed. Results 
showed a significant inhibitory effect, near 30%, on E705 
cells proliferation in a concentration dependent man-
ner. The higher concentration of plantaricin 1053 (1 µg/
mL) evidenced the higher inhibitory effect, as reported in 
Fig. 8.
Also in this case a possible role for plantaricin P1053 
in the complex pathway triggered by EGFR activation 
in cancerogenic cell lines, was evaluated. For this, cells 
were treated in the same manner with plantaricin P1053 
for different times (0 min, 30 min, 1 h, 3 h and 24 h). By 
Western blot analysis no phosphorylation of Akt or Erk 
was detected, although both proteins were detected in 
their unphosphorylated forms (data not shown).
Discussion
This work describes the isolation and characterization 
of a bacteriocin-like compound produced by Lactobacil-
lus plantarum strain PBS067 that shows an antimicro-
bial activity against potential human pathogens and that 
Table 2 Minimum inhibitory concentration (MIC) 
of  the  growth measured by  plantaricin P1053 isolated 
from L. plantarum strain PBS067 against E. coli ATCC 25922 
and S. aureus ATCC 6538
Plantaricin P1053 
(μg/mL)
E. coli ATCC 25922 
growth inhibition (%)
S. aureus ATCC 6538 
growth inhibition (%)
250.00 65.74 89.55
125.00 62.70 91.29
62.50 64.12 96.02
31.25 62.95 69.25
15.62 66.25 0.00
7.81 68.85 0.00
3.90 14.41 0.00
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Fig. 6 Evaluation of cell viability on normal CCD 841 cell line after 
treatment with plantaricin P1053. MTT test was performed on normal 
CCD 841 cell line. Buffer NaCl 0.1 M pH 2 was used as control and 
it did not have any effect on cell viability. Values are presented as 
mean ± SD. Statistical analyses were performed using the Student’s 
t-test. *p < 0.05
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affects both normal and cancerogenic human intestinal 
cells. The probiotic strain, isolated from healthy patients, 
was able to produce the maximum amount of a bacteri-
ocin-like compound at the onset of the stationary phase 
of the growth, during an incubation for 16 h at 37 °C at 
pH 4. This result is quite similar to that showed by Messi 
et al. (2001), who reported that L. plantarum 35d started 
to produce bacteriocin during the late logarithmic 
growth phase. Plantaricin 35d reached the maximum 
concentration after 19 h of incubation (stationary phase), 
at pH 4.
Preliminary experiments evidenced that the cell free 
supernatant (CFS) of Lactobacillus plantarum PBS067 
culture had an inhibition of the antagonist bacteria 
growth, as E. coli and S. aureus. Thus, a purification pro-
cedure of the CFS metabolites was performed.
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Fig. 7 Western blotting analysis of EGFR pathway activation after exposure to plantaricin P1053 in CCD 841 cell line. Representative western 
blotting analyses performed on crude extracts, using anti-P-AKT, anti-AKT, anti-P-ERK1/2, anti-ERK1/2 and anti-GAPDH antibodies. GAPDH was used 
as a control. The experiments were performed in triplicate (a). Densitometric analysis performed with Scion Image Software. Values are expressed by 
comparing the data obtained after the treatment with plantaricin P1053 with those obtained from 0’ of exposition to the compound (b). Values are 
presented as mean ± SD. ND, no protein phosphorylation was detected
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Fig. 8 Evaluation of cell viability on E705 cancer colon cell line after treatment with plantaricin P1053. MTT test was performed on cancerogenic 
E705 cell line. Buffer NaCl 0.1 M pH 2 was used as control and it did not have any effect on cell viability (100% viability). Values are presented as 
mean ± SD. Statistical analyses were performed using the Student’s t-test. *p < 0.05
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On the basis of the pH dependence, we decided to use 
the adsorption/desorption method as the first step in the 
purification procedure (Yang et al. 1992). The second step 
of purification consisted of the extraction with a solvent 
like n-butanol, and the last consisted of the elution in 
SEC-HPLC. At each purification step, the antibacterial 
activity was tested and a comparison of the activity of the 
acidified purified compound in respect to the crude CFS, 
was verified. Results showed an increase of the antimi-
crobial activity along the purification procedure.
The purified compound from supernatant of L. plan-
tarum strain PBS067 was then characterized. An 
enzymatic hydrolytic activity by proteinase K was dem-
onstrated on the isolated compound.
The mass analysis by ESI-full MS determined a molec-
ular mass of 1053  Da for the compound (plantaricin 
P1053). Because of its bactericidal activity, its behavior 
based on the hydrophobicity and the charge of the bioac-
tive compound secreted by the cells, pH resistance and 
low molecular mass, plantaricin P1053 could be classi-
fied as a small bacteriocin-like presumably belonging to 
Class II, according to the definition given by Klaenham-
mer (1993).
Our data are in line with the results obtained by Zhao 
et  al., where for the first time a plantaricin with a low 
molecular weight of 1044 Da able to act against Bacillus 
spp. was isolated from L. plantarum strain JLA-9 (Zhao 
et  al. 2016) and obtained by Zhu et  al. that described 
the identification of the plantaricin ZJ008 with a MW 
of 1335 Da able to act against Gram-positive and Gram-
negative bacteria (Zhu et al. 2014).
Interestingly, this paper demonstrates not only that the 
bacteriocin-like compound isolated from L. plantarum 
PBS067 showed a broad range of antimicrobial activity 
towards Gram-positive and Gram-negative bacteria with 
a good MIC, but also its activity towards human cells, 
extending its role from a bacteriocin to a multifunctional 
factor that has effect both on normal and cancer cells.
In fact, in this work we investigated also plantaricin 
P1053 effect towards human cells using both healthy and 
cancerogenic cell lines. Plantaricin P1053 was tested on 
human intestinal epithelial cells. Unlike other authors, 
like Dimitrovski et al. (2014) who used the supernatant of 
the broth culture, in this study we administered only the 
bacteriocin-like molecule resuspended in NaCl buffer. 
The plantaricin P1053 increased the vitality of healthy 
CCD 841 cell line. These results made us speculate that 
this bacteriocin-like compound could act on pathways 
involved in cell survival and proliferation, such as the epi-
dermal growth factor receptor (EGFR) pathway. We have 
decided to investigate this pathway because it has been 
reported by Wang et al. (2014) that a Lactobacillus rham-
nosus GG-derived soluble protein, p40, is able to activate 
EGFR and its downstream target Akt in intestinal epi-
thelial cells, leading to an inhibition of apoptosis and a 
preservation of the barrier function by an upregulation of 
mucin production. Moreover, Tao et al. (2005) reported 
that a soluble factor from the probiotic strain Lactoba-
cillus rhamnosus GG could rapidly activate the MAPKs. 
The activation of EGFR, Akt and Erk was therefore inves-
tigated after plantaricin P1053 administration at different 
times. This compound is able to rapidly activate, within 
30 min, Akt and Erk in healthy intestinal cells. The phos-
phorylation of Akt leads to an anti-apoptotic effect, while 
Erk activation is pro-proliferative. It is important to note 
that Akt and Erk activation is finely controlled, with a 
decrease in their phosphorylation level till a nearly switch 
off 24 h after treatment.
Concerning the effect of plantaricin P1053 on cancero-
genic epithelial cell lines, we observed a significant loss 
of viability, near the 30%, of E705 cells in a concentra-
tion dependent manner. These data are in line with those 
of Dimitrovski et  al. on different cancerogenic cell lines 
(Dimitrovski et  al. 2014), although they used only the 
supernatant obtained from L. plantarum cultures.
SDS-PAGE electrophoresis showed no Akt and Erk 
activation in cancerogenic E705 cells, leading us to think 
that the difference in the vitality between healthy and 
cancer cells is due to EGFR downstream targets activa-
tion in the former. Moreover, our experiments show that 
plantaricin P1053 is able to reduce E705 cancer cells via-
bility, although the mechanism involved is still not elu-
cidated; at the same time its effect on healthy intestinal 
cells is an increase in viability, due to a transient phos-
phorylation of both Akt and Erk which is achieved with a 
different timing and is readily switched off in 24 h.
In conclusion, in this paper we have demonstrated 
that the antimicrobial activity of L. plantarum PBS067 is 
mediated by the plantaricin P1053 action. The novelty of 
the paper is that in addition to exhibiting an antimicro-
bial activity against both representative Gram-positive 
and Gram-negative bacteria, this compound can also 
affect the host cells through an enhancing of healthy cells 
and a reduction of cancer cells viability. Although some 
molecular mechanisms must be elucidated in further 
studies, plantaricin P1053 could represent one of the first 
multifunctional bacteriocin-like compound on human 
epithelial intestinal cells.
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